Mirum Pharmaceuticals (MIRM) just posted Q1 2026 results with revenue of US$159.9 million, a basic EPS loss of US$13.43 and net income loss excluding extra items of US$790.2 million. The company has reported quarterly revenue of US$99.4 million in Q4 2024, US$111.6 million in Q1 2025, US$127.8 million in Q2 2025, US$133.0 million in Q3 2025 and US$148.9 million in Q4 2025, while EPS over those periods ranged between a loss of US$0.50 and a profit of US$0.06. For investors, a key focus this quarter is how far current margins are from breakeven and what that gap indicates about the path toward more efficient profitability.

See our full analysis for Mirum Pharmaceuticals.

With the headline numbers on the table, the next step is to compare them with the dominant narratives around Mirum Pharmaceuticals and identify which of those stories the latest margins and recent trends actually support.

Loss swings from single digits to US$790 million

• Net income excluding extra items moved from a loss of US$5.7 million in Q4 2025 to a loss of US$790.2 million in Q1 2026, while trailing twelve month losses widened from US$23.4 million to US$798.8 million over the last four reported periods.
• What stands out against the bearish narrative is that analysts expect revenue to grow about 18.4% to 23.4% per year and margins to move from roughly mid single digit losses toward positive territory in the next three years. At the same time, the latest quarterly loss is far larger than the recent quarterly range of about US$24 million to a small profit, which keeps bears focused on execution risk around costs and pipeline spending.
  • Bears point to five year loss growth of about 17.2% per year and the dependence on a concentrated rare disease portfolio as reasons this type of large quarterly loss could recur if trials, reimbursement or competition do not go to plan.
  • At the same time, the trailing twelve month revenue of US$569.6 million sits well above the US$336.9 million level a few reporting periods ago, which is the part of the recent data that aligns more closely with the idea in the bearish narrative that the underlying business can still expand even while profitability is pressured.

On quarters like this, skeptics argue the business model is being stress tested and that investors should understand exactly how the cautious narrative frames those risks before taking a view on the stock's recovery path 🐻 Mirum Pharmaceuticals Bear Case.

Revenue above US$550 million but still unprofitable

• On a trailing basis Mirum generated US$569.6 million of revenue with a basic EPS loss of US$15.16, compared with earlier trailing periods between US$336.9 million and US$521.3 million of revenue and EPS losses between US$1.85 and US$1.61.
• Supporters of the bullish narrative argue that forecasts for revenue growth of about 23.4% per year and earnings growth of about 79.07% per year, along with expectations of profitability within three years, remain grounded in the fact that quarterly revenue has stepped from US$99.4 million in Q4 2024 to US$159.9 million in Q1 2026 even though the latest earnings loss is very large.
  • The bullish view leans on ideas like expanded patient identification and international launches as drivers of that higher top line, while the sequence of recent net income results, which ranged from a loss of US$23.8 million to a small profit before the Q1 2026 loss, shows why bulls pay close attention to whether this quarter is treated as an outlier.
  • At the same time, historical widening losses and the need for ongoing R&D and SG&A spending are exactly the areas where the current numbers still challenge the most optimistic bullish assumptions about how quickly margins can move toward the mid teens or higher.

Bulls and skeptics are both watching whether future quarters look more like the earlier near breakeven periods or like this one, and the bullish narrative lays out what would need to go right for the stronger scenario to play out 🐂 Mirum Pharmaceuticals Bull Case.

DCF value far above price, but losses still growing

• The stock trades at US$102.93 while the provided DCF fair value is US$369.77 and the allowed analyst price target reference is US$139.36, yet trailing twelve month net income excluding extra items shows a loss of about US$798.8 million and five year losses have grown at about 17.2% per year.
• Consensus style commentary highlights a trade off where forecasts call for revenue growth of about 21.3% per year and an eventual return to profitability. However, recent dilution and the current P/S of 11x, which sits slightly below peers at 12.9x and slightly above the broader US Biotechs group at 10.9x, suggest the market is still heavily discounting the DCF fair value and price target until the large loss profile begins to moderate.
  • The wide gap between the US$102.93 share price, the US$139.36 analyst target level and the US$369.77 DCF fair value level makes the forecasts for margin improvement and revenue expansion central to any thesis, because the current earnings track record alone does not explain those higher valuation anchors.
  • Shareholder dilution over the past year also matters here, since any future improvement in earnings per share will have to work against a larger share count, which is an example of how capital raising choices feed directly into whether the implied upside can be realised on a per share basis.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Mirum Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seen enough to sense both the optimism and the concern around Mirum Pharmaceuticals? Act while the details are fresh and weigh the trade off yourself by checking 3 key rewards and 1 important warning sign.

Explore Alternatives

Mirum Pharmaceuticals currently carries very large trailing losses of about US$798.8 million, widening from prior periods, which keeps risk and execution firmly in focus.

If that kind of volatility makes you uneasy, balance your watchlist by checking companies highlighted in the 72 resilient stocks with low risk scores that aim to keep downside risk in check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.